You are about to leave jnjmedicaldevices.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
Biosense Webster – Health Economics & Outcomes Research
AF Burden of Disease and Treatment
As a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, Biosense Webster, Inc. is committed to patient advocacy and raising awareness of atrial fibrillation and its available treatment options.
Atrial Fibrillation is a chronic and typically progressive disease, which burdens patients with frequent and repeated episodes over their lifetime.2
AF increases a patient’s risk of life-threatening complications, such as stroke, heart attack, and heart failure.2 Patients with AF have a 46% higher risk of mortality than individuals without AF.2,3
Atrial Fibrillation Burden of Disease Report
The AF Burden of Disease Report outlines the growing burden of AF on patients, caregivers and healthcare systems across Europe, emphasizing the scale and impact of the disease.
Atrial Fibrillation Management Report
The Atrial Fibrillation Management Report details 2020 guideline-recommended treatment options for AF as well as their long-term impact on clinical, patient and economic outcomes, aiming to support healthcare professionals (HCPs) when making treatment decisions.
1. Zoni‐Berisso M, Lercari F, Carazza T, Domenicucci S (2014) Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 6 213‐220
2. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG et al. (2016) Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta‐ analysis. Bmj 354 i4482.
3. Boriani G, Proietti M (2017) Atrial fibrillation prevention: an appraisal of current evidence. Heart